The University of Iowa

Publications

Final Results of the RHAPSODY Trial: A Multi‐Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A‐APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen...

Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Haley EC, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Haacke EM, Fawaz M, Davis TP, Toga AQ, Griffin JH, Zlokovic BV, the NeuroNEXT Clinical Trials Network NN104 Investigators.
Annals of Neurology. 2019 Jan; 85 125-36.
PubMed: 
PMC6342508

Feasibility and safety of lumbar puncture in the Parkinson's Disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey CS, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Simuni T, on behalf of the Parkinson's Progression Markers Initiative Steering Committee, Study Cores, Site Investigators, Coordinators, and Industry & Scientific Advisory Board.
Parkinsonism & Related Disorders. 2019; 62 201-209.
PubMed: 
30738748

Recruitment & Retention Program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

Bartlett A, Kolb SJ, Kinglsey A, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnett BW, Werner K, Thangarajh M, Shieh PB, Finanger E, Coffey CS, Yankey JW, Cudkowicz ME, McGovern MM, McNeil ED, Arnold DW, Kissel JT, The NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.
Contemporary Clinical Trials Communications. 2018 Sep; 11 113-119.
PubMed: 
PMC6072892